MedTrace Logo

Effect of Prebiotics in Saudi Adults With Type 2 Diabetes

NCT07464691 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-11

No results posted yet for this study

Summary

This study will explore how a natural food ingredient called oligofructose affects blood glucose levels, lipid profiles, inflammation biomarkers, and gut bacteria in Saudi adults with type 2 diabetes. Oligofructose is a type of dietary fiber found in foods such as onions, garlic, and bananas. It is known to help the growth of "good" bacteria in the intestine, which may improve digestion and metabolism.

A total of 100 adults (50 with type 2 diabetes and 50 without diabetes) will take part in this research. Participants will be randomly assigned to receive either oligofructose or a placebo twice daily for 12 weeks. Blood tests will be done at the beginning and at weeks 4, 8, and 12 to check changes in blood glucose, lipid profiles, and inflammation.

The goal of this study is to find out whether adding oligofructose to the diet can help people with diabetes improve their blood glucose control, reduce inflammation, and support a healthier balance of gut bacteria.

Conditions

Interventions

DIETARY_SUPPLEMENT

oligofructose

Dose: 16 g/day (two 8 g doses) Form: Powder, dissolved in warm drinks Route: Oral

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Dose: 8 g/day (two 4 g doses) Form: Powder, dissolved in warm drinks Route: Oral

Sponsors & Collaborators

  • Princess Nourah Bint Abdulrahman University

    lead OTHER

Principal Investigators

  • Nahla M. Bawazeer, PhD · Princess Nourah Bint Abdulrahman University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-13
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464691 on ClinicalTrials.gov